Illumina Ventures

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

Iambic Therapeutics focuses on accelerating molecular discovery through its innovative quantum molecular simulation engine. By integrating artificial intelligence and automated synthetic development, the company aims to enhance the design of small-molecule therapeutics. This technology significantly improves the accuracy of molecular predictions, providing valuable insights for therapeutic discovery. Iambic Therapeutics is committed to transforming the drug development process, enabling physicians to access more precise molecular data and ultimately improving treatment outcomes.

Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution, the Naica System. This platform leverages advanced microfluidic technology to provide a flexible and accessible tool for high-resolution genetic analysis. By enabling compatibility with multiple chemistries and offering multiplex capabilities, Stilla Technologies aims to simplify the processes of image analysis and data exploration for researchers in various fields, including life sciences and therapeutics. The company's mission is to make digital PCR a standard tool across all areas of genetic research and application.

Tagomics is a company focused on enhancing disease diagnosis through advanced multitopic profiling and epigenetic-based technologies. It specializes in the development of chemicals that facilitate the discovery of epigenetic biomarkers, providing a second layer of information to DNA beyond the traditional genetic code. This innovative approach enables the identification of biological markers that are sensitive to lifestyle, environmental factors, and disease states. By concentrating on early detection, particularly for colorectal and other common cancers, Tagomics aims to improve patient outcomes through more effective and cost-efficient diagnostic methods.

Actym Therapeutics is a biotechnology company based in Berkeley, California, dedicated to developing innovative immuno-oncology therapies for cancer treatment. Founded in 2017, the company has created a unique therapeutic platform known as STACT (S. Typhimurium-Attenuated Cancer Therapy), which uses an attenuated microbial approach to target solid tumors while sparing healthy tissue. This platform allows for the delivery of multiple immuno-modulatory payloads directly to immune cells residing within tumors, addressing challenges faced by traditional therapies. In preclinical studies, STACT has shown promise in enhancing treatment efficacy by engaging various biological pathways from a single therapy. The company successfully secured $34 million in a Series A financing round in April 2020, which was co-led by prominent venture funds, highlighting its potential in the biopharmaceutical landscape.

Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition.

Iambic Therapeutics focuses on accelerating molecular discovery through its innovative quantum molecular simulation engine. By integrating artificial intelligence and automated synthetic development, the company aims to enhance the design of small-molecule therapeutics. This technology significantly improves the accuracy of molecular predictions, providing valuable insights for therapeutic discovery. Iambic Therapeutics is committed to transforming the drug development process, enabling physicians to access more precise molecular data and ultimately improving treatment outcomes.

Broken String Biosciences is focused on creating a sequencing platform that enhances the assessment of genome stability, aiming to facilitate the development of safer cell and gene therapies. The company integrates advanced sequencing techniques with bioinformatics and artificial intelligence, enabling healthcare professionals to utilize a data-driven approach for the safe introduction of innovative medicines. Through its novel tools, Broken String Biosciences seeks to unlock advancements in therapeutic options, contributing to the evolution of medical treatments.

Lightcast Discovery Limited, founded in 2019 and based in Cambridge, United Kingdom, specializes in advancing drug discovery through its innovative microfluidic platform. This technology allows for precise control of thousands of droplets, enabling complex cell analysis and workflows without manual manipulation. By leveraging this platform, Lightcast collaborates with major pharmaceutical companies and leading academic institutions to develop new therapies and products. The company's focus is on pushing the boundaries of complex cell analysis, thereby facilitating the discovery of unique clinical approaches in the field of drug development.

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

Pluton Biosciences is a bioscience research company that specializes in the testing and discovery of microbes for the development of various products, primarily focusing on biopesticides and pharmaceuticals. Utilizing an innovative platform, the company mines and clones microbes to generate a range of beneficial products aimed at enhancing biopesticides, crop protection, human health, and bioremediation. By harnessing the potential of bacteria, fungi, and viruses, Pluton Biosciences enables medical researchers and agricultural professionals to explore sustainable and all-natural solutions for various applications, contributing to advancements in both environmental and health-related sectors.

Pattern Bioscience, operating as Klaris Diagnostics, is a clinical diagnostics company focused on addressing antibiotic resistance. Founded in 2014 and based in Austin, Texas, the company has developed a next-generation clinical microbiology platform utilizing patented phenotypic single-cell technology. This innovative platform, known as Digital Culture technology, facilitates rapid pathogen identification and antibiotic susceptibility testing, providing results within hours rather than days. By integrating single-cell analysis with artificial intelligence pattern recognition, Pattern Bioscience bypasses traditional culture steps, leading to a more comprehensive and reliable diagnosis that encompasses all potential resistance mechanisms. This approach aims to enhance diagnostic accuracy and speed, significantly improving patient care in the face of growing concerns about antibiotic resistance.

Protillion Biosciences is a biotechnology company focused on transforming therapeutic antibody and drug discovery through innovative technology. It has developed a high-throughput protein engineering platform that aims to enhance the efficiency and effectiveness of protein-based drug design and development. By utilizing a novel protein display technology, Protillion seeks to improve the productivity of biologic research and development, enabling healthcare professionals to more rapidly discover and develop new protein therapeutics. The company's approach is intended to modernize traditional methods in the field, ultimately contributing to advancements in healthcare.

SonoThera is a biotechnology company focused on developing non-viral genetic therapies using ultrasound technology. The company aims to create genetic medicines that address the root causes of human diseases, particularly for conditions that currently have limited or no effective treatments. By leveraging ultrasound-guided nonviral gene therapy, SonoThera seeks to enhance treatment options and improve health outcomes for millions of patients.

LetsGetChecked is an at-home health testing platform that connects customers with regulated laboratory testing, enabling individuals to manage their health effectively. Based in New York, the company offers a wide range of testing kits for general wellness, sexual health, women's health, men's health, and specific illnesses, including cancer and fertility issues. Users can order testing kits online, collect samples such as blood or urine, and return them using prepaid envelopes. The analyzed results are then uploaded online, providing customers with convenient access to their health information. LetsGetChecked operates nationwide in the United States and extends its services to Canada and Europe, promoting a patient-led approach to healthcare through technology.

Sherlock Biosciences is a biotechnology company based in Cambridge, Massachusetts, focused on developing molecular diagnostic solutions. Incorporated in 2018, the company utilizes cutting-edge engineering biology tools, including CRISPR and synthetic biology, to create innovative diagnostic platforms. Its primary products include SHERLOCK, a CRISPR-based method for detecting and quantifying specific genetic sequences, and INSPECTR, a synthetic biology-based diagnostics platform. These technologies aim to provide rapid, accurate, and affordable results across various applications, including precision oncology, infection identification, food safety, at-home testing, and disease detection. By leveraging these advanced tools, Sherlock Biosciences addresses the need for effective diagnostics in both high and low-resource settings.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution, the Naica System. This platform leverages advanced microfluidic technology to provide a flexible and accessible tool for high-resolution genetic analysis. By enabling compatibility with multiple chemistries and offering multiplex capabilities, Stilla Technologies aims to simplify the processes of image analysis and data exploration for researchers in various fields, including life sciences and therapeutics. The company's mission is to make digital PCR a standard tool across all areas of genetic research and application.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

RedShift BioAnalytics, Inc. specializes in analytical instrumentation for the research, development, and manufacture of protein therapeutic drugs and biopharmaceutical products. The company offers ProLaser, a benchtop instrument designed for the rapid characterization of proteins throughout various stages, including lead candidate selection, formulation development, process optimization, stability measurement, and routine analytics. Additionally, RedShift BioAnalytics has developed a Microfluidic Modulation Spectroscopy (MMS) platform, tailored specifically to meet the needs of protein scientists by providing advanced data analytics and direct measurement of structural changes in proteins that affect drug efficacy and quality. Established in 2005 and based in Burlington, Massachusetts, the company serves the life sciences and biopharmaceutical markets. It was previously known as RedShift Systems Corporation until its name change in August 2016.

Walking Fish Therapeutics is focused on creating cell-based therapeutics that utilize the unique capabilities of B cells to activate the immune system for cancer treatment. The company is developing a platform that aims to function as in vivo protein factories, producing replacement proteins for deficiency diseases and engineered antibodies. By harnessing the power of locally acting proteins, Walking Fish Therapeutics seeks to address serious health conditions across oncology, regenerative medicine, and autoimmune diseases, ultimately enabling healthcare providers to concentrate on innovative therapeutic approaches in these fields.

Alamar Biosciences, founded in 2018 and based in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that enhances protein analysis and the diagnosis of various diseases through innovative antibody technologies. By facilitating the discovery of new biomarkers, Alamar aims to empower healthcare providers to identify diseases at an early stage, thereby improving potential treatment outcomes and patient care.

Genome Medical, Inc. is a genomic medicine delivery company based in South San Francisco, California, established in 2016. It operates a technology platform known as Genome Care Delivery, which connects individuals and healthcare providers with genetic specialists to facilitate virtual genetic consultations. The company focuses on various areas of clinical care, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacogenomics. By providing expert genetic assessments and personalized clinical action plans, Genome Medical helps patients understand their genetic risks and make informed treatment decisions. Additionally, the company supports healthcare providers in navigating the growing field of genetics, enhancing disease diagnosis, and improving patient care while aiming to reduce overall healthcare costs.

NanoCellect Biomedical, Inc. is a company based in San Diego, California, specializing in the development of innovative flow cytometry and cell sorting technologies for life science researchers. Founded in 2009, it offers the WOLF Cell Sorter, which utilizes a closed fluid-path microfluidic cartridge to enable efficient cell sorting while minimizing biohazard risks and shear stress associated with traditional methods. The company’s portfolio includes affordable and compact microfluidic-based instruments and consumables that facilitate cellular analysis essential for drug discovery, single cell-omics, cloning, antibody discovery, and basic research. By simplifying the process of analyzing and sorting distinct cell populations, NanoCellect Biomedical supports biomedical scientists in advancing their research and improving personalized medicine.

LetsGetChecked is an at-home health testing platform that connects customers with regulated laboratory testing, enabling individuals to manage their health effectively. Based in New York, the company offers a wide range of testing kits for general wellness, sexual health, women's health, men's health, and specific illnesses, including cancer and fertility issues. Users can order testing kits online, collect samples such as blood or urine, and return them using prepaid envelopes. The analyzed results are then uploaded online, providing customers with convenient access to their health information. LetsGetChecked operates nationwide in the United States and extends its services to Canada and Europe, promoting a patient-led approach to healthcare through technology.

NanoCellect Biomedical, Inc. is a company based in San Diego, California, specializing in the development of innovative flow cytometry and cell sorting technologies for life science researchers. Founded in 2009, it offers the WOLF Cell Sorter, which utilizes a closed fluid-path microfluidic cartridge to enable efficient cell sorting while minimizing biohazard risks and shear stress associated with traditional methods. The company’s portfolio includes affordable and compact microfluidic-based instruments and consumables that facilitate cellular analysis essential for drug discovery, single cell-omics, cloning, antibody discovery, and basic research. By simplifying the process of analyzing and sorting distinct cell populations, NanoCellect Biomedical supports biomedical scientists in advancing their research and improving personalized medicine.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2019, the company utilizes artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By employing machine learning techniques, Delfi Diagnostics develops high-precision, non-invasive tests that aim to detect cancer at a stage when it is most treatable. Their technology enables healthcare professionals to recognize previously unrecognized cancer-associated cell-free DNA fragments, facilitating timely and effective treatment options for patients.

Rebus Biosystems, Inc. is a life science technology company based in Santa Clara, California, specializing in spatial omics tools. The company has developed the Rebus Esper, an automated spatial omics platform that integrates advanced imaging, on-system chemistry, and user-friendly software to deliver quantitative data at subcellular resolution. This platform allows researchers to analyze biological molecules across large tissue sections while preserving spatial context. Rebus Biosystems focuses on automating microfluidics for sequential labeling of expressed transcripts, enabling high-resolution imaging that supports applications in pharmaceutical research, particularly in visualizing gene expression profiles in human brain tissues. Founded in 2006 and formerly known as Optical Biosystems, Rebus Biosystems continues to innovate in the realm of spatial omics to enhance research capabilities.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

Encoded Therapeutics, Inc. is a biotechnology company that specializes in precision gene therapies aimed at treating a wide array of severe genetic disorders. Utilizing a unique platform, Encoded identifies sequences within the human genome that regulate gene expression through advanced screening and computational techniques. The company's therapy pipeline targets both genetic and acquired disorders across various disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and based in South San Francisco, California, Encoded Therapeutics is focused on developing innovative solutions that enable medical practitioners to improve patient outcomes and enhance quality of life.

Pattern Bioscience, operating as Klaris Diagnostics, is a clinical diagnostics company focused on addressing antibiotic resistance. Founded in 2014 and based in Austin, Texas, the company has developed a next-generation clinical microbiology platform utilizing patented phenotypic single-cell technology. This innovative platform, known as Digital Culture technology, facilitates rapid pathogen identification and antibiotic susceptibility testing, providing results within hours rather than days. By integrating single-cell analysis with artificial intelligence pattern recognition, Pattern Bioscience bypasses traditional culture steps, leading to a more comprehensive and reliable diagnosis that encompasses all potential resistance mechanisms. This approach aims to enhance diagnostic accuracy and speed, significantly improving patient care in the face of growing concerns about antibiotic resistance.

Genome Medical, Inc. is a genomic medicine delivery company based in South San Francisco, California, established in 2016. It operates a technology platform known as Genome Care Delivery, which connects individuals and healthcare providers with genetic specialists to facilitate virtual genetic consultations. The company focuses on various areas of clinical care, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacogenomics. By providing expert genetic assessments and personalized clinical action plans, Genome Medical helps patients understand their genetic risks and make informed treatment decisions. Additionally, the company supports healthcare providers in navigating the growing field of genetics, enhancing disease diagnosis, and improving patient care while aiming to reduce overall healthcare costs.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients facing cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, SQZ Biotech can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide array of clinical challenges. The company aims to create well-tolerated cell therapies that not only enhance therapeutic benefits but also improve the overall patient experience compared to traditional cell therapy methods. Through a combination of internal research initiatives and external collaborations, SQZ Biotech is advancing a new generation of cellular therapies aimed at both immune activation and immune suppression.

LetsGetChecked is an at-home health testing platform that connects customers with regulated laboratory testing, enabling individuals to manage their health effectively. Based in New York, the company offers a wide range of testing kits for general wellness, sexual health, women's health, men's health, and specific illnesses, including cancer and fertility issues. Users can order testing kits online, collect samples such as blood or urine, and return them using prepaid envelopes. The analyzed results are then uploaded online, providing customers with convenient access to their health information. LetsGetChecked operates nationwide in the United States and extends its services to Canada and Europe, promoting a patient-led approach to healthcare through technology.

Actym Therapeutics is a biotechnology company based in Berkeley, California, dedicated to developing innovative immuno-oncology therapies for cancer treatment. Founded in 2017, the company has created a unique therapeutic platform known as STACT (S. Typhimurium-Attenuated Cancer Therapy), which uses an attenuated microbial approach to target solid tumors while sparing healthy tissue. This platform allows for the delivery of multiple immuno-modulatory payloads directly to immune cells residing within tumors, addressing challenges faced by traditional therapies. In preclinical studies, STACT has shown promise in enhancing treatment efficacy by engaging various biological pathways from a single therapy. The company successfully secured $34 million in a Series A financing round in April 2020, which was co-led by prominent venture funds, highlighting its potential in the biopharmaceutical landscape.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution, the Naica System. This platform leverages advanced microfluidic technology to provide a flexible and accessible tool for high-resolution genetic analysis. By enabling compatibility with multiple chemistries and offering multiplex capabilities, Stilla Technologies aims to simplify the processes of image analysis and data exploration for researchers in various fields, including life sciences and therapeutics. The company's mission is to make digital PCR a standard tool across all areas of genetic research and application.

Fluent BioSciences is a life science company focused on single-cell technology, specializing in molecular analysis of cells without the need for complex microfluidic instrumentation. Its proprietary platform, Pre-Templated Instant Partitions (PIPseqTM), facilitates the rapid self-assembly of individual cells or molecules into millions of uniform partitions, allowing for sensitive and unbiased preparation of proteins and nucleic acids for sequencing applications. This innovative technology enhances accessibility to single-cell, molecule, and protein analysis, thereby broadening market access for researchers in biotechnology, pharmaceuticals, and academic institutions.

Ribometrix, Inc. is a biotechnology company based in Durham, North Carolina, focused on discovering and developing small molecule drugs that target functional three-dimensional RNA structures to treat various human diseases. Established in 2014, the company utilizes advanced expertise in RNA structural analysis to identify novel small molecules that can inhibit the production of proteins associated with diseases. Ribometrix's innovative platform combines proprietary RNA structure determination techniques with cutting-edge RNA tools and artificial intelligence capabilities, allowing researchers to effectively analyze and manipulate RNA biology. The company operates scientific offices in a renovated Biolabs space in Durham, along with additional offices in Chapel Hill and Boston.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2019, the company utilizes artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By employing machine learning techniques, Delfi Diagnostics develops high-precision, non-invasive tests that aim to detect cancer at a stage when it is most treatable. Their technology enables healthcare professionals to recognize previously unrecognized cancer-associated cell-free DNA fragments, facilitating timely and effective treatment options for patients.

Cradle Genomics, Inc. specializes in fetal genetic analysis and pregnancy health screening solutions, focusing on non-invasive prenatal testing (NIPT) to provide comprehensive insights at the earliest stages of pregnancy. Founded in 2018 and headquartered in San Diego, California, with research and development operations in Detroit, Michigan, the company has developed a platform that analyzes genetic material from fetal cells collected during a first trimester visit. This approach allows pregnant women to receive critical information about their health and the health of their developing fetus without any risk. Cradle Genomics aims to empower expectant parents with knowledge that can guide their decisions throughout the pregnancy journey.

Encoded Therapeutics, Inc. is a biotechnology company that specializes in precision gene therapies aimed at treating a wide array of severe genetic disorders. Utilizing a unique platform, Encoded identifies sequences within the human genome that regulate gene expression through advanced screening and computational techniques. The company's therapy pipeline targets both genetic and acquired disorders across various disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and based in South San Francisco, California, Encoded Therapeutics is focused on developing innovative solutions that enable medical practitioners to improve patient outcomes and enhance quality of life.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

LunaDNA is a community-owned platform that facilitates the sharing of health and DNA data for medical research. Founded by the creators of Illumina, a leader in DNA sequencing, LunaDNA addresses the issue of siloed genomic data by providing individuals with a compelling incentive to share their health information. Participants are rewarded with shares in the database, allowing them to benefit from the profits generated by medical research and discoveries. This model not only empowers users to contribute their health records, genomic data, and personal health experiences but also fosters a sense of community ownership. As researchers pay to access the data for their studies, the proceeds are distributed back to the community, akin to dividends. By prioritizing privacy and trust, LunaDNA aims to increase participation in genomic research while facilitating advancements in healthcare that can ultimately save lives.

LunaPBC, Inc. is a Public Benefit Corporation based in San Diego, California, that develops a community-owned platform for genomic and medical research. The company's primary offering, LunaDNA, serves as a knowledge database where individuals can share their health and DNA data to contribute to health research and drive medical discoveries. This platform is designed to benefit both non-profit and for-profit health research projects, facilitating collaboration among pharmaceutical, insurance, and healthcare IT companies. In addition to advancing medical research, LunaPBC allows its members to share in the financial benefits derived from medical breakthroughs, promoting a model of shared community ownership.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution, the Naica System. This platform leverages advanced microfluidic technology to provide a flexible and accessible tool for high-resolution genetic analysis. By enabling compatibility with multiple chemistries and offering multiplex capabilities, Stilla Technologies aims to simplify the processes of image analysis and data exploration for researchers in various fields, including life sciences and therapeutics. The company's mission is to make digital PCR a standard tool across all areas of genetic research and application.

Ribometrix, Inc. is a biotechnology company based in Durham, North Carolina, focused on discovering and developing small molecule drugs that target functional three-dimensional RNA structures to treat various human diseases. Established in 2014, the company utilizes advanced expertise in RNA structural analysis to identify novel small molecules that can inhibit the production of proteins associated with diseases. Ribometrix's innovative platform combines proprietary RNA structure determination techniques with cutting-edge RNA tools and artificial intelligence capabilities, allowing researchers to effectively analyze and manipulate RNA biology. The company operates scientific offices in a renovated Biolabs space in Durham, along with additional offices in Chapel Hill and Boston.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients facing cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, SQZ Biotech can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide array of clinical challenges. The company aims to create well-tolerated cell therapies that not only enhance therapeutic benefits but also improve the overall patient experience compared to traditional cell therapy methods. Through a combination of internal research initiatives and external collaborations, SQZ Biotech is advancing a new generation of cellular therapies aimed at both immune activation and immune suppression.

LunaDNA is a community-owned platform that facilitates the sharing of health and DNA data for medical research. Founded by the creators of Illumina, a leader in DNA sequencing, LunaDNA addresses the issue of siloed genomic data by providing individuals with a compelling incentive to share their health information. Participants are rewarded with shares in the database, allowing them to benefit from the profits generated by medical research and discoveries. This model not only empowers users to contribute their health records, genomic data, and personal health experiences but also fosters a sense of community ownership. As researchers pay to access the data for their studies, the proceeds are distributed back to the community, akin to dividends. By prioritizing privacy and trust, LunaDNA aims to increase participation in genomic research while facilitating advancements in healthcare that can ultimately save lives.

Cernostics, Inc. is a diagnostics company based in Pittsburgh, Pennsylvania, specializing in cancer diagnostics and prognostics through a tissue systems biology approach. Founded in 2008, Cernostics develops the TissueCypher Barrett’s esophagus assay, which utilizes whole slide digital imaging technology to assess the risk for patients with Barrett’s esophagus, thereby reducing uncertainty in treatment decisions for gastroenterologists. The company's patent-protected TissueCypher platform analyzes whole slide digital images using multiplexed fluorescence, enhancing the accuracy of traditional tissue diagnostics by evaluating tumors as complex systems comprised of multiple cell types. Additionally, Cernostics operates a high-complexity clinical reference laboratory that supports biomarker discovery, validation, and clinical trial efforts, ultimately aiming to improve patient outcomes and reduce healthcare costs. The company has established a strategic collaboration with Deciphex Limited to further its capabilities in spatial biology and AI-driven image analytics.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

NanoCellect Biomedical, Inc. is a company based in San Diego, California, specializing in the development of innovative flow cytometry and cell sorting technologies for life science researchers. Founded in 2009, it offers the WOLF Cell Sorter, which utilizes a closed fluid-path microfluidic cartridge to enable efficient cell sorting while minimizing biohazard risks and shear stress associated with traditional methods. The company’s portfolio includes affordable and compact microfluidic-based instruments and consumables that facilitate cellular analysis essential for drug discovery, single cell-omics, cloning, antibody discovery, and basic research. By simplifying the process of analyzing and sorting distinct cell populations, NanoCellect Biomedical supports biomedical scientists in advancing their research and improving personalized medicine.

Genome Medical, Inc. is a genomic medicine delivery company based in South San Francisco, California, established in 2016. It operates a technology platform known as Genome Care Delivery, which connects individuals and healthcare providers with genetic specialists to facilitate virtual genetic consultations. The company focuses on various areas of clinical care, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacogenomics. By providing expert genetic assessments and personalized clinical action plans, Genome Medical helps patients understand their genetic risks and make informed treatment decisions. Additionally, the company supports healthcare providers in navigating the growing field of genetics, enhancing disease diagnosis, and improving patient care while aiming to reduce overall healthcare costs.

LunaDNA is a community-owned platform that facilitates the sharing of health and DNA data for medical research. Founded by the creators of Illumina, a leader in DNA sequencing, LunaDNA addresses the issue of siloed genomic data by providing individuals with a compelling incentive to share their health information. Participants are rewarded with shares in the database, allowing them to benefit from the profits generated by medical research and discoveries. This model not only empowers users to contribute their health records, genomic data, and personal health experiences but also fosters a sense of community ownership. As researchers pay to access the data for their studies, the proceeds are distributed back to the community, akin to dividends. By prioritizing privacy and trust, LunaDNA aims to increase participation in genomic research while facilitating advancements in healthcare that can ultimately save lives.

NanoCellect Biomedical, Inc. is a company based in San Diego, California, specializing in the development of innovative flow cytometry and cell sorting technologies for life science researchers. Founded in 2009, it offers the WOLF Cell Sorter, which utilizes a closed fluid-path microfluidic cartridge to enable efficient cell sorting while minimizing biohazard risks and shear stress associated with traditional methods. The company’s portfolio includes affordable and compact microfluidic-based instruments and consumables that facilitate cellular analysis essential for drug discovery, single cell-omics, cloning, antibody discovery, and basic research. By simplifying the process of analyzing and sorting distinct cell populations, NanoCellect Biomedical supports biomedical scientists in advancing their research and improving personalized medicine.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

Serimmune Inc. is a biotechnology company focused on developing diagnostics and therapeutics for autoimmune diseases. Founded in 2014 and based in Goleta, California, the company utilizes its serum epitope repertoire analysis (SERA) technology platform, which integrates bacterial display peptide libraries, sequencing, machine learning, and custom bioinformatics. This platform enables the comprehensive profiling of antibody repertoires and the identification of antigens and epitopes linked to various health conditions, including infections, allergens, microbiome organisms, autoimmune diseases, and cancers. By decoding the human immune response, Serimmune aims to empower the creation of innovative diagnostics, vaccines, and therapeutic solutions.

Genome Medical, Inc. is a genomic medicine delivery company based in South San Francisco, California, established in 2016. It operates a technology platform known as Genome Care Delivery, which connects individuals and healthcare providers with genetic specialists to facilitate virtual genetic consultations. The company focuses on various areas of clinical care, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacogenomics. By providing expert genetic assessments and personalized clinical action plans, Genome Medical helps patients understand their genetic risks and make informed treatment decisions. Additionally, the company supports healthcare providers in navigating the growing field of genetics, enhancing disease diagnosis, and improving patient care while aiming to reduce overall healthcare costs.

Human Longevity (HLI) is a genomic-based health intelligence company focused on proactive healthcare and enhancing quality of life. Founded in 2013 and headquartered in San Diego, California, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with advanced machine learning techniques, to drive medical discoveries and transform healthcare practices. The company operates multiple business areas, including the HLI Health Nucleus, a clinical research center that employs whole-genome sequencing, advanced imaging, and curated personal health data to provide an in-depth understanding of individual health. HLI's platform also addresses age-related decline in stem cell function and focuses on major health issues such as cancer, diabetes, obesity, heart and liver diseases, and dementia. By integrating DNA sequencing with expert analysis, HLI aims to empower individuals to take control of their health and shift medical care from a reactive to a proactive approach.

Twist Bioscience Corporation is a synthetic biology company that specializes in the manufacture and sale of synthetic DNA-based products. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes a proprietary semiconductor-based DNA synthesis platform that writes DNA on silicon chips, allowing for the rapid and cost-effective production of high-quality synthetic DNA. Twist Bioscience's offerings include synthetic genes, tools for sample preparation, antibody libraries for drug discovery, and DNA as a medium for digital data storage. The company serves various sectors, including healthcare, agriculture, and industrial chemicals, supporting customers in their efforts to enhance lives and promote sustainability. Through its innovative platform, Twist Bioscience aims to overcome traditional inefficiencies in DNA synthesis, enabling researchers to accelerate their projects.

Desktop Genetics is an international biotechnology company to helps researchers discover and treat the root genetic causes of human disease. Desktop Genetics is a recognized leader in genome editing technology, staffed by a dedicated team of genome editing experts, bioinformaticians, and data scientists. The company's tools and technologies are used by organizations all over the world. It enables the work of their pharma, biotech, and academic customers working in drug discovery and functional genomics.

Biota specializes in DNA sequencing and data science to analyze the earth's subsurface, primarily serving the oil and gas industry. The company offers comprehensive services including sample acquisition, data extraction, sequencing, and analysis, which help clients enhance reservoir economics while minimizing environmental impact. By providing actionable diagnostics, Biota enables oil and gas companies to gain valuable insights into drainage volumes, well connectivity, and engineered completions. Its patented technology has been successfully applied to over 500 wells, primarily by leading producers in the US Shale market, delivering significant economic value and promoting sustainable production practices.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

23andMe, Inc. is a consumer genetics and research company headquartered in Sunnyvale, California, founded in 2006. It specializes in providing direct-to-consumer personal genome services through home-based saliva collection kits. The company offers a range of services, including Health + Ancestry, which provides insights into ancestry, traits, and health, and Ancestry + Traits, which details ancestry breakdown and various trait reports. 23andMe aims to help individuals understand their genetic makeup, enabling users to explore their ancestry, genealogy, and inherited traits. Additionally, the company markets its services to researchers and scientists, offering categorized and searchable genetic data. With a focus on consumer and research services, 23andMe is positioned within the rapidly growing biotech and healthcare sectors, contributing to the understanding of genetics and its implications for health.